Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual MeetingGlobeNewsWire • 11/09/20
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Iovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020GlobeNewsWire • 10/30/20
Was The Smart Money Right About Crowding Into Iovance Biotherapeutics, Inc. (IOVA)?Insider Monkey • 10/29/20
Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual MeetingGlobeNewsWire • 10/14/20
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVAPRNewsWire • 10/10/20
Iovance's stock tumbles over questions about regulatory submission for melanoma drugMarket Watch • 10/06/20
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic MelanomaGlobeNewsWire • 10/05/20
Iovance Biotherapeutics (IOVA) Down 1.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/05/20
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/06/20
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020GlobeNewsWire • 07/23/20
Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?Zacks Investment Research • 06/04/20
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public OfferingGlobeNewsWire • 06/02/20